Free Educational Webinar for Journalists, Shareholders, and
Investment Professionals
International Stem Cell Corporation (OTCBB:ISCO)
(www.intlstemcell.com),
the first company to perfect a method of creating human
"parthenogenetic" stem cells from unfertilized eggs, will host a webinar
titled "Stem Cells 102: Beyond Embryonic Stem Cell Research," Thursday,
March 12, 2009, from 1:00pm-2:00pm EDT. This free educational webinar is
for journalists, shareholders, and investment professionals interested
in learning about new emerging technology in the stem cell research
arena.
Please note that space is limited. Interested parties are invited to
make a reservation to participate in the webinar by using the following
link: https://www2.gotomeeting.com/register/560601521
Covered in the webinar:
-
What is a pluripotent stem cell?
-
What are the implications of the FDA's recent approval of Geron
clinical trials?
-
What is parthenogenesis and how does this process solve certain
ethical and immune rejection issues that have long shadowed stem cell
research?
-
How close are we to treating diseases with stem cells?
The company is hosting this event due to renewed interest in the sector
given the FDA's recent approval of human trials of embryonic stem cells
and President Obama's commitment to lifting federal research bans.
For more news and information on International Stem Cell Corporation
please visit www.IRGnews.com/coi/ISCO
where you can find the CEO's video, a fact sheet on the company,
investor presentations, and more. ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):
International Stem Cell Corporation is a California biotechnology
company focused on developing therapeutic and research products. ISCO's
technology, Parthenogenesis, results in the creation of
pluripotent human stem cell lines from unfertilized human eggs. ISCO
scientists have created the first Parthenogenetic homozygous stem
cell line (phSC-Hhom-4) that can be a source of therapeutic cells
that will minimize immune rejection after transplantation into hundreds
of millions of individuals of differing sexes, ages and racial groups.
These advancements offer the potential to create the first true "Stem
Cell Bank" and address ethical issues by eliminating the need to use or
destroy fertilized embryos. ISCO also produces and markets specialized
cells and growth media worldwide for therapeutic research through its
subsidiary Lifeline Cell Technology. For more information, visit the
ISCO website at: www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
FORWARD-LOOKING STATEMENTS: Statements pertaining to anticipated future financial and/or
operating results, future growth in research, technology, clinical
development and potential joint venture and other opportunities for the
company and its subsidiary, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements that
are not historical fact (including, but not limited to statements that
contain words such as "will," "believes," "plans," "anticipates,"
"expects," "estimates,") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties,
including, without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, application of capital resources among competing uses,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities
and Exchange Commission filings. The company disclaims any intent or
obligation to update these forward-looking statements.
Key Words: Stem Cells, Biotechnology, Parthenogenesis
International Stem Cell Corporation Kenneth C. Aldrich, Chairman,
CEO 760-940-6383 kaldrich@intlstemcell.com or Jeffrey
Janus, President 760-940-6383 jjanus@intlstemcell.com or The
Investor Relations Group 212-825-3210 Investor Relations: Adam
S. Holdsworth aholdsworth@investorrelationsgroup.com or Media
Relations: Laura Colontrelle lcolontrelle@investorrelationsgroup.com |